|
Pharmacy |
Pharmacists must complete a Masters degree in Pharmacy (MPharm) and a year of supervised practice (the pre-registration year) before registering with the Royal Pharmaceutical Society of Great Britain.
The MPharm Pharmacy undergraduate course is run by the School of Pharmacy at Keele. Pharmacy students need to be able to integrate concepts from many disciplines in order to understand the diagnosis and treatment of human diseases. The course is delivered by staff within the School of Pharmacy with expertise in these relevant disciplines in collaboration with colleagues from the School of Physical and Geographical Sciences, School of Medicine and School of Life Sciences.
Master in Pharmacy programmes are accredited by the Royal Pharmaceutical Society of Great Britain (RPSGB) and ‘Pharmacist’ is a protected title. Graduates from MPharm programmes must carry out a period of assessed pre-registration training in order to register with the RPSGB and to enter practice. Consequently, the MPharm degree is viewed as a vocational programme and is a pre-requisite for pre-registration study. In common with all other UK Schools of Pharmacy, Keele requires external accreditation of its course by the RPSGB. The MPharm programme is subject to annual inspection and approval by the RPSGB, working towards full accreditation when the first cohort of students graduates. All modules in the MPharm programme are core and students will not be granted exemptions for any modules or assessments.
Further details of the following modules, including course outlines, can be found on the MPharm course website: www.keele.ac.uk/schools/pharm
| Semester 1-2 | C/O | TYP | ECTS | CATS | ||
| # | PHA-10014 | MPharm Programme Level I | C | M | 60 | 120 |
| The Level I programme provides a truly integrated and fully contextualised introduction to the Keele MPharm degree. The programme is based upon a single 120-credit module that comprises three cycles of learning, assessment and reflection, and all topics progress logically and coherently with patient-oriented themes. The principal aim is to develop knowledge and skills in a wide variety of disciplines by demonstrating the linkages between seemingly disparate topics in science and practice that underpin all subsequent learning. Rather than packaging material into small, discrete modules, the Level I programme allows students to develop a deeper understanding of the topics covered: for example, examination of the structure and function of DNA and mRNA is preceded by studies in the basic chemistry which governs chemical bonding and molecular structure, and is followed by in-depth analyses of genetics and patient care. Studies in metabolism are underpinned by the principles of structure and bonding, and are delivered alongside topics in bioenergetics and reaction kinetics. Studies in pharmacy practice are supported throughout the programme by practical dispensing classes and developing topics in the essential and pharmaceutical sciences. In this way, the linkages between all strands of the programme are made clear and students equipped to study the later levels of the course. Within the three cycles of learning and assessment material has been contextualised into three broad contexts: those of individual people/patients, of people/patients as members of families, and of wider populations. This is strengthened in later cycles by focussing upon particular patient groups, and upon specific diseases which affect these groups. Throughout, the relevance of each group of teaching sessions to the healthcare of the individual, family or population will be highlighted. | ||||||
| Semester 1-2 | C/O | TYP | ECTS | CATS | ||
| # | PHA-20009 | MPharm Programme Level II | C | M | 60 | 120 |
| The Level II programme continues to provide a truly integrated and fully contextualised course of study as part of the Keele MPharm degree. In an identical manner to the Level I programme, the Level II programme is based upon a single 120-credit module that comprises cycles of learning, assessment and reflection, and all topics progress logically and coherently with patient-oriented themes. The principal aim is to further develop knowledge and skills in a wide variety of disciplines by demonstrating the linkages between applied topics in science and practice that underpin all subsequent learning. The Level II programme allows students to further develop a deeper understanding of the topics covered at Level I and see how they are applied in the pharmaceutical sciences and pharmacy practice. Topics are sometimes highlighted with overt links to Level I; for example, aspects of physical chemistry and the analysis of small organic molecules is fundamental to an appreciation of the Pharmaceutical Science and Formulation theme in Cycle 1, and fundamental studies of metabolism lead to a deeper understanding of metabolic interrelationships and the metabolism of xenobiotics in the Pharmacology and Drug Action theme of Cycle 2. Similarly, the dispensing course at Level II follows on directly from the equivalent theme in Level I. Also included in the Level II programme is a visit to a pharmaceutical company that specialises in liquid formulations so students will be able to experience the manufacture of pharmaceuticals on an industrial scale. | ||||||
| Semester 1-2 | C/O | TYP | ECTS | CATS | ||
| PHA-30010 | MPharm Programme Level III | C | M | 60 | 120 | |
| Level III of the MPharm programme has been consolidated into one single 120-credit unit, enabling a continuum of learning that is centred upon the development of key clinical and therapeutic skills. The white paper "Pharmacy for England", the document "Life Sciences Blueprint" and the GPhC proposals for pharmacists' education prior to registration, steer the view that the MPharm curriculum must be further developed to meet the demands of the future Pharmacy workforce, primarily through the enhancement of clinical pharmacy and pharmacology content. This enhancement provides many opportunities to increase students&© engagement with therapeutics but the revised Keele MPharm Level III programme can take this further, by developing the work that is already in hand to better direct integrated study of pharmacology, pharmaceutics and therapeutics in the context of patient care. | ||||||